Eleven Biotherapeutics (EBIO) Misses Q4 EPS by 13c

Eleven Biotherapeutics (NASDAQ: EBIO) reported Q4 EPS of ($0.49), $0.13 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $375 million versus the consensus estimate of $800 thousand.

For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• YesAsia Holdings Replicates Record High Half-Year Results: Revenue Grows 23.2% to US$301.51 Million; Net Profit Surges 30.0% to US$18.30 Million
• Chile's Codelco posts stronger profit on copper rally as mine disruptions drag on output